Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
BANGALORE, India, August 7, 2013 /PRNewswire/ --
The Investigational New Drug (IND) relates to a novel molecule targeting prostate cancer which will now progress towards the next stage of development, with clinical trials expected next year
Jubilant Biosys Ltd., a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., announced today the US FDA acceptance of the IND filing for a novel molecule targeting prostate cancer with Endo Pharmaceuticals of the US. This molecule will now progress towards the next phase of development and is anticipated to go into clinical trials by late 2013.
(Logo: http://photos.prnewswire.com/prnh/20130807/633652 )
"We are very pleased and elated with this successful outcome, which is the result of excellent collaboration between the scientists at Endo and Jubilant Biosys. Being at the forefront of pharmaceutical, life sciences and healthcare innovation, Jubilant pursues its goal to enable affordable healthcare to patients worldwide," said Dr. Subir Kumar Basak, President, Global Drug Discovery Services, Jubilant Life Sciences.
Added Dr. Sandeep Gupta, Senior Vice President, Discovery & Early Development, Endo Pharmaceuticals, "I congratulate the Jubilant and Endo teams on achieving this important milestone. It was their outstanding collaborative work and ingenuity that enabled the successful filing and acceptance of an IND in less than three years. The IND filing and progression of the molecule to the next stage of development further validates Endo's unique collaborative drug discovery approach which aims to address unmet medical needs and improve patient outcomes."
The multi-target oncology collaboration between Jubilant and Endo began four years ago, and is focused on developing best-in-class, differentiated therapies that address the unmet needs of cancer patients worldwide. The collaboration has delivered on multiple milestones across the discovery continuum.
About Jubilant Biosys
Jubilant Biosys Ltd. is a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd. which is headquartered in Noida, India. It provides integrated drug discovery solutions to the global pharmaceutical industry. Biosys has pioneered the risk-shared collaborative discovery research model and demonstrated their capabilities over the years through multiple partnerships with global pharmaceutical firms in the therapeutic areas of oncology, metabolic disorders, pain and inflammation, and so on. http://www.jubilantbiosys.com
About Jubilant Life Sciences
Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. It also provides services in Contract Manufacturing of Sterile Injectables and Ointments, Creams and Liquids and Drug Discovery and Development. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of over 6,200 multicultural people across the globe, the Company is committed to delivering value to its customers spread across 98 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: http://www.jubl.com
Help employers find you! Check out all the jobs and post your resume.